ArticleNPJ vaccines2026
Live-vectored antigen cocktail confers protection against African swine fever virus (ASFV) Georgia 2007/1 challenge.
Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- MGF100 but not MGF300 family is a potential multigene-deleted target for ASFV attenuation and live attenuated vaccine development.Virulence · 2026Article
- Genotype II Live-Attenuated ASFV Vaccine Bearing 24 Genes Deletion in 3 Independent Regions Is Able to Provide Complete Protection Against Homologous Lethal Challenge.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Dual Antiviral Functions of Antibodies Targeting African Swine Fever Virus p17 Protein: Viral Inhibition and ADCC Induction.Viruses · 2026Article
- Current Insights into the Epidemiology and Transmission Dynamics of African Swine Fever Virus and Future Control Perspectives.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
African swine fever (ASF) is a lethal disease of swine caused by the ASF virus (ASFV), for which no licensed vaccine is currently available in non-endemic countries. Here, replication-competent adenovirus-vectored ASFV multi-antigen constructs were shown to express ASFV antigens in primary swine cells. Pigs immunized with a cocktail of these constructs, with or without Quil-A adjuvant, tolerated the formulation well. The constructs elicited robust ASFV-specific IgG responses (p < 0.0001), which were boosted upon reimmunization (p < 0.05). Following challenge with the virulent ASFV Georgia 2007/1 strain using a natural transmission model, five of six pigs vaccinated without Quil-A survived, while all pigs receiving adjuvanted constructs succumbed to ASF. Survivors cleared the virus, exhibited only mild clinical signs, gained weight, and remained healthy for the remainder of the study. Histopathological analysis revealed an absence of ASFV-associated lesions in survivors, whereas severe lesions were observed in pigs vaccinated with adjuvanted constructs and in negative controls. Although neutralizing antibodies were undetectable, granzyme B-producing CD8α⁺ T cell responses were observed in survivors, indicating a likely correlation for cellular immunity in protection. These findings highlight the protective potential of ASFV antigen expression constructs and inform subunit vaccine design.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.